GC3111

GC3111 is a tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine developed for booster immunization in adolescents and adults. It contains reduced quantities of diphtheria toxoid (DT), tetanus toxoid (TT), and acellular pertussis antigens including pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN). The vaccine is designed to stimulate both humoral and cell-mediated immune responses against Bordetella pertussis, Corynebacterium diphtheriae, and Clostridium tetani. Preclinical studies demonstrated that the immunogenicity of enhanced GC3111 was equivalent to existing commercial Tdap vaccines such as Boostrix in terms of antibody production and cytokine expression. The mechanism of action is immunostimulation via presentation of bacterial antigens to the immune system[1][2][4]. The developer is GC Biopharma (formerly known as Green Cross or GC Pharma)[2]. As of April 2022, it was in phase II clinical trials for prevention of diphtheria, tetanus, and pertussis[2].

Other names

GC3111 vaccineGC-3111 vaccineGC 3111 vaccineGreen Cross Tdap vaccine